Topics

HER2/HER3 Antibody Therapeutic Shows Potential in NRG1-Fusion-Positive Solid Tumors

19:00 EST 8 Nov 2019 | Cancer Networks

MCLA-128 showed radiological and clinical responses in patients with certain types of cancer who harbored neuregulin 1 gene fusions.

Original Article: HER2/HER3 Antibody Therapeutic Shows Potential in NRG1-Fusion-Positive Solid Tumors

NEXT ARTICLE

More From BioPortfolio on "HER2/HER3 Antibody Therapeutic Shows Potential in NRG1-Fusion-Positive Solid Tumors"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...